In a multicentric general-practice-study 2504 hyperlipoproteinemic patients were treated with etofibrate retard for 4 weeks. The drug was administered once daily in the evening. A highly significant decrease of the mean values of cholesterol around 18.4% and 27.6% resp., and of the mean triglycerides between 31.3% and 16.5% resp. were observed. The atherogenic index was reduced by 28%. The simultaneous, highly significant reduction of blood glucose and of uric acid levels as well as of blood pressure showed the comprising effects of etofibrate retard against the atherosclerosis and its risk factors. The excellent tolerance of the drug was stated by more than 99% of the patients treated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
Arzneimittelforschung
May 1996
National Research Programme for Nutritional Intervention, Medical Research Council, Tygerberg, South Africa.
In dyslipidemic or hyperlipidemic patients etofibrate (CAS 31637-97-5, active principle of Lipo-Merz-retard) improves plasma lipoprotein profiles by reducing low density lipoprotein cholesterol and triglycerides. Experimentally, it also promotes fibrinolysis and thrombolysis and reduces the susceptibility of lipoproteins to oxidative stress. In order to investigate the possible efficacy of etofibrate on atherosclerosis, a study in African Green Monkeys was performed.
View Article and Find Full Text PDFIn a pilot study the therapeutic effect of 2 x 500 mg etofibrate (Lipo Merz retard) on lipids and lipoproteins, fibrinolytic activity and clinical parameters was studied for four weeks in hyperlipidemic patients suffering from arteriosclerosis obliterans (Fontaine stage II/III). The study parameters were evaluated prior to and after the four weeks of treatment. Administration of etofibrate resulted in a significant decrease in serum cholesterol and triglyceride levels, the decrease in LDL-/HDL-cholesterol-ratio due mainly to an elevation of the HDL-cholesterol fraction, an increase in plasma fibrinolytic activity, an increased peripheral blood flow in the ischemic leg, and an increase in the pain-free walking distance.
View Article and Find Full Text PDFRelative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
Arzneimittelforschung
April 1985
The relative bioavailability of 2-(p-chlorophenoxy)-2-methylpropionic acid [2-(nicotinyloxy)-ethyl]-ester (etofibrate) from Lipo-Merz retard (500 mg) with respect to Lipo-Merz (600 mg) has been determined in 10 health volunteers in a crossover study. Etofibrate was determined in plasma after hydrolysis to clofibrinic acid. Pharmacokinetic parameters were derived to describe the plasma concentration-time profiles using a minimisation of least squares technique.
View Article and Find Full Text PDFIn a multicentric general-practice-study 2504 hyperlipoproteinemic patients were treated with etofibrate retard for 4 weeks. The drug was administered once daily in the evening. A highly significant decrease of the mean values of cholesterol around 18.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!